Paul Carlier, a professor in the Department of Chemistry in the Virginia Tech College of Science and director of the Virginia Tech Center for Drug Discovery, and his colleagues received a $3.7 million grant from the National Institutes of Health to begin further testing of two inexpensive and effective antimalarial drug candidates that can kill Plasmodium parasites at three different stages of their development.
- Paul Carlier, Chair of the VaDDC, Receives Grant to Study Promising Antimalarial Drugs
- Norwegian researchers have shown that a phosphatase (PRL-3) inhibitor developed by VaDDC Exec. Comm. member John Lazo might be useful to treat cancer
- Webster Santos, Virginia Tech drug researcher receives $2.2 million NIH grant to further develop “fat burning” molecule
- VaDDC Executive Committee Member, Beth Sharlow Receives Promotion at UVA
- Virginia Company, Phlow Corp. Awarded $354 million to Produce Ingredients for Covid-19 Drugs